Mirador Capital Partners’s CRISPR Therapeutics CRSP Stock Holding History

Mirador Capital Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,536	Closed	-$297K	–	202
2024 Q4	$297K	Buy	+7,536	New	+$356K	0.05%	158
2024 Q2	–	Sell	-2,980	Closed	-$203K	–	197
2024 Q1	$203K	Buy	+2,980	New	+$213K	0.04%	184
2023 Q1	–	Sell	-4,940	Closed	-$201K	–	192
2022 Q4	$201K	Buy	4,940 +467	+10%	+$24.8K	0.05%	184
2022 Q3	$292K	Buy	4,473 +262	+6%	+$19K	0.07%	162
2022 Q2	$256K	Buy	4,211 +54	+1%	+$3.17K	0.06%	165
2022 Q1	$261K	Sell	4,157 -54	-1%	-$3.39K	0.05%	183
2021 Q4	$319K	Buy	+4,211	New	+$368K	0.07%	182

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mirador Capital Partners's CRSP Position: Q1 2025 in Review

Mirador Capital Partners sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 7,536 shares — an estimated $297K sold.

Mirador Capital Partners first reported a position in CRSP in Q4 2021 and held it in 7 quarters. The position peaked at $319K in Q4 2021. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

Mirador Capital Partners reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
Mirador Capital Partners sold 7,536 CRISPR Therapeutics shares in Q1 2025, an estimated $297K.
Mirador Capital Partners first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 7 quarters.
Mirador Capital Partners's CRISPR Therapeutics position peaked at $319K in Q4 2021.
396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Mirador Capital Partners's 13F filing for Q1 2025, filed 9 Apr 2025.